INFI News and Press, Infinity Pharmaceuticals Inc. From 02/11/19

The following slide deck was published by Infinity Pharmaceuticals, Inc. in conjunction with this Read more ...

NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Conagra Brands Inc. (NYSE:CAG), National Retail Properties (NYSE:NNN),...

CAMBRIDGE, Mass. , Feb. 4, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins , Infinity Pharmaceutical's Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February 11, 2019 , at 10:00 a.m. ...

Infinity Pharmaecuticals (NASDAQ: INFI ) provides a business update ahead of a presentation at the JPMorgan healthcare conference. More news on: Infinity Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

CAMBRIDGE, Mass. , Jan. 7, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced anticipated 2019 milestones for IPI-549, a first-in-class, oral, immuno-oncology product candidate targeting tumor-associated myeloid cells through selective phosphoinositide-3-ki...

Infinity Pharmaceuticals, Inc. (INFI) Q3 2018 Earnings Conference Call November 5, 2018 4:30 PM ET Executives Jayne Kauffman – Senior Executive Coordinator Adelene Perkins – Chief Executive Officer Larry Bloch – President Sam Agresta – Chief Medical ...

Infinity Pharmaceuticals (NASDAQ: INFI ): Q3 GAAP EPS of $0.23 beats by $0.36 . More news on: Infinity Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Consumer stocks news, , Read more ...

CAMBRIDGE, Mass. , Nov. 5, 2018 /PRNewswire/ --  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2018 financial results and provided an update on the company and its progress with IPI-549, a first-in-class oral immuno-oncology product candidate that s...

Bristol-Myers Squibb (NYSE: BMY ) and Infinity Pharmaceuticals (NASDAQ: INFI ) will collaborate on a clinical trial evaluating the combination of Opdivo (nivolumab) and IPI-549, a PI3K-gamma inhibitor, in patients with advanced urothelial cancer who have progressed after platinum-based che...

-- Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H’19-- Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combinati...